WO2001012214A3 - MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) - Google Patents

MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) Download PDF

Info

Publication number
WO2001012214A3
WO2001012214A3 PCT/EP2000/007666 EP0007666W WO0112214A3 WO 2001012214 A3 WO2001012214 A3 WO 2001012214A3 EP 0007666 W EP0007666 W EP 0007666W WO 0112214 A3 WO0112214 A3 WO 0112214A3
Authority
WO
WIPO (PCT)
Prior art keywords
ifn
peg
association
mycophenolate mofetil
therapeutically effective
Prior art date
Application number
PCT/EP2000/007666
Other languages
French (fr)
Other versions
WO2001012214A2 (en
Inventor
Mary Catherine Graves
Stephen Christopher Pappas
Friederike Zahm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL00357367A priority Critical patent/PL357367A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to EP00962297A priority patent/EP1220683A2/en
Priority to IL14761200A priority patent/IL147612A0/en
Priority to KR1020027001782A priority patent/KR20020020809A/en
Priority to MXPA02001296A priority patent/MXPA02001296A/en
Priority to JP2001516559A priority patent/JP2003507339A/en
Priority to CA002380653A priority patent/CA2380653A1/en
Priority to BR0013252-7A priority patent/BR0013252A/en
Priority to AU74082/00A priority patent/AU7408200A/en
Publication of WO2001012214A2 publication Critical patent/WO2001012214A2/en
Publication of WO2001012214A3 publication Critical patent/WO2001012214A3/en
Priority to NO20020704A priority patent/NO20020704L/en
Priority to HK03101248.5A priority patent/HK1048951A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The use of therapeutically effective amount of IFN- α or PEG-IFN-α in association with a therapeutically effective amount of a pharmaceutically acceptable salt or prodrug of mycophenolic acid for the manufacture of medicaments for treating liver diseases patients. The components are administered over a period of time at least sufficient to reduce the amount of HCV-RNA present in the peripheral blood of said patient to less than 100 copies/ml at 24 weeks after the end of treatment.
PCT/EP2000/007666 1999-08-13 2000-08-08 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) WO2001012214A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2001516559A JP2003507339A (en) 1999-08-13 2000-08-08 Mycophenolate mofetil in combination with PEG-IFN-α
EP00962297A EP1220683A2 (en) 1999-08-13 2000-08-08 Mycophenolate mofetil in association with peg-ifn-alpha
IL14761200A IL147612A0 (en) 1999-08-13 2000-08-08 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PREG-IFN-α
KR1020027001782A KR20020020809A (en) 1999-08-13 2000-08-08 Mycophenolate mofetil in association with peg-ifn-alpha
MXPA02001296A MXPA02001296A (en) 1999-08-13 2000-08-08 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-alpha.
PL00357367A PL357367A1 (en) 1999-08-13 2000-08-08 Mycophenolate mofetil in association with peg-ifn-alpha
CA002380653A CA2380653A1 (en) 1999-08-13 2000-08-08 Mycophenolate mofetil in association with peg-ifn-.alpha.
BR0013252-7A BR0013252A (en) 1999-08-13 2000-08-08 Mycophenolate mofetil in combination with peg-ifn-alfa
AU74082/00A AU7408200A (en) 1999-08-13 2000-08-08 Mycophenolate mofetil in association with peg-ifn-alpha
NO20020704A NO20020704L (en) 1999-08-13 2002-02-12 Mycophenolate mofetil associated with PEG-IFN- <alfa>
HK03101248.5A HK1048951A1 (en) 1999-08-13 2003-02-19 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-α

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99115950.0 1999-08-13
EP99115950 1999-08-13
US18790700P 2000-03-08 2000-03-08
US60/187,907 2000-03-08

Publications (2)

Publication Number Publication Date
WO2001012214A2 WO2001012214A2 (en) 2001-02-22
WO2001012214A3 true WO2001012214A3 (en) 2001-10-04

Family

ID=29762814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007666 WO2001012214A2 (en) 1999-08-13 2000-08-08 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)

Country Status (14)

Country Link
EP (1) EP1220683A2 (en)
JP (1) JP2003507339A (en)
CN (1) CN1368887A (en)
AU (1) AU7408200A (en)
BR (1) BR0013252A (en)
CA (1) CA2380653A1 (en)
HU (1) HUP0202525A3 (en)
MX (1) MXPA02001296A (en)
PE (1) PE20010490A1 (en)
PL (1) PL357367A1 (en)
RU (1) RU2002105485A (en)
TR (1) TR200200401T2 (en)
WO (1) WO2001012214A2 (en)
ZA (1) ZA200200280B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
SI1719773T1 (en) 2004-02-24 2009-08-31 Japan Tobacco Inc Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
US7632491B2 (en) * 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
WO2010110503A1 (en) * 2009-03-27 2010-09-30 주식회사 중외제약 INTERFERON-α (IFN-α) FUSED PROTEIN HAVING IFN-α AND CYTOPLASMIC TRANSDUCTION PEPTIDE (CTP)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012013117U1 (en) 2011-10-21 2015-01-16 Abbvie Inc. Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV)
DE112012003510T5 (en) 2011-10-21 2015-03-19 Abbvie Inc. Method for the treatment of HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
JP6820841B2 (en) * 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション Dosing regimen for pegged interferon
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048840A1 (en) * 1997-04-29 1998-11-05 Schering Corporation Polyethylene glycol-interferon alpha conjugates for therapy of infection
WO2000050064A2 (en) * 1999-02-26 2000-08-31 Institute Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048840A1 (en) * 1997-04-29 1998-11-05 Schering Corporation Polyethylene glycol-interferon alpha conjugates for therapy of infection
WO2000050064A2 (en) * 1999-02-26 2000-08-31 Institute Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KWO P Y ET AL: "Combination therapy with ribavirin plus alpha-interferon is beneficial for the treatment of chronic hepatitis C in patients who have failed treatment with alpha-interferon.", GASTROENTEROLOGY, vol. 116, no. 4 PART 2, April 1999 (1999-04-01), Digestive Disease Week and the 100th Annual Meeting of the American Gastroenterological Association;Orlando, Florida, USA; May 16-19, 1999, pages A1235, XP000990387, ISSN: 0016-5085 *
PLATZ K P ET AL: "INDICATIONS FOR MYCOPHENOLATE MOFETIL THERAPY IN HEPATITIS C-PATIENTS UNDERGOING LIVER TRANSPLANTATION", TRANSPLANTATION PROCEEDINGS,US,ORLANDO, FL, vol. 30, no. 4, June 1998 (1998-06-01), pages 1468 - 1469, XP000889647, ISSN: 0041-1345 *
POL S ET AL: "Ribavirin + Inerferon-alfa 2B combination shows increased efficiency compared to high doses alfa INF, alone in naive patients infected by genotype 1B", HEPATOLOGY,US,WILLIAMS AND WILKINS, BALTIMORE, MD, vol. 28, no. 4, PART 02, October 1998 (1998-10-01), pages 507A, XP002110250, ISSN: 0270-9139 *

Also Published As

Publication number Publication date
MXPA02001296A (en) 2002-07-22
PL357367A1 (en) 2004-07-26
CN1368887A (en) 2002-09-11
TR200200401T2 (en) 2002-06-21
WO2001012214A2 (en) 2001-02-22
RU2002105485A (en) 2004-01-27
EP1220683A2 (en) 2002-07-10
JP2003507339A (en) 2003-02-25
AU7408200A (en) 2001-03-13
PE20010490A1 (en) 2001-04-27
BR0013252A (en) 2002-04-16
CA2380653A1 (en) 2001-02-22
ZA200200280B (en) 2003-04-11
HUP0202525A3 (en) 2003-11-28
HUP0202525A2 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
BR9306841A (en) Pharmaceutical composition process for providing an antihistamine treatment which does not induce any significant cardiac arrhythmia in a human patient and use of a composition for the manufacture of a medicine for use in an antihistamine treatment
RU2003119460A (en) APPLICATION OF PEG-INTERFERON-A (PEG-INF-A) AND RIBAVIRIN FOR TREATMENT OF CHRONIC HEPATITIS C
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
WO2000041504A3 (en) Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
IL158155A (en) Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
JP2001520994A5 (en)
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
JP2002544227A5 (en)
JP2003514025A5 (en)
AR025549A1 (en) MICOFELONATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALFA
JP2002530353A5 (en)
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
YU9302A (en) Mycophenolate mofetil in association with peg-ifn-alpha
RU2002129298A (en) APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER&#39;S DISEASE
DE69531166D1 (en) MEDICINAL PRODUCT TO RELEASE THE SIDE EFFECTS CAUSED BY IMMUNE SUPPRESSIVES
JP2002529515A5 (en)
ZA933567B (en) Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer&#39;s disease
ECSP003616A (en) MOFETIL MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALFA
RU2005131943A (en) MEDICINAL AND / OR PREVENTIVE MEANS FOR CHRONIC SKIN DISEASES
TH54147A (en) Mycophenolate Mofitilano to join with PEG-IFN-Alpha
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
UY26292A1 (en) MYCOPHENOLATE MOFETILE IN ASSOCIATION WITH PEG-IFN-A LAW 17164
TH54147B (en) Mycofinolate, mophitilano, joining with PEG-IFN -a
WO2004050019A3 (en) Method and compositions for treating anxiety

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-93/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 147612

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 516672

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2380653

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 74082/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000962297

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008113971

Country of ref document: CN

Ref document number: PA/a/2002/001296

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: P20020118A

Country of ref document: HR

Ref document number: IN/PCT/2002/207/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020027001782

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV2002-526

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002/00401

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2002 2002105485

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027001782

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000962297

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-526

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1020027001782

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000962297

Country of ref document: EP